Skip to main content
. 2019 Jan 9;9(3):729–736. doi: 10.1534/g3.118.200901

Figure 3.

Figure 3

The risk variant of rs76562819 results in a genotype-dependent decrease in IL-13 induced promoter activity of CAPN14. A, Diagrams of constructs containing the CAPN14 promoter are shown. B, Reporter constructs were transfected into esophageal epithelial cells followed by treatment with or without IL-13 (100 ng/mL) for 24 h. For each sample, nanoluciferase activity was normalized to firefly luciferase activity. Data are shown as mean ± SEM (***, t-test p-value < 0.001; 2-way ANOVA: P < 0.05, genotype P < 0.0001 accounting for 12.6% of total variation; n = 3 per group; data representative of three independent experiments).